Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 3/20 | 0.39 |
| ▸ | BACE1 | P56817 | 10/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 6/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | STAT3 | P40763 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL892208 | 1.00 | AKR1B1 (0.39) | AKR1B1BACE1CTSDAPPSMN1; SMN2 | |
| SCHEMBL10209435 | 1.00 | AKR1B1 (0.39) | AKR1B1BACE1CTSDAPPSMN1; SMN2 | |
| SCHEMBL10209412 | 0.92 | AKR1B1 (0.39) | AKR1B1BACE1CTSDAPPSMN1; SMN2 | |
| SCHEMBL10268860 | 0.92 | AKR1B1 (0.39) | AKR1B1BACE1CTSDAPPSMN1; SMN2 | |
| SCHEMBL892330 | 0.92 | AKR1B1 (0.39) | AKR1B1BACE1CTSDAPPSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL12491275 | 0.91 | AKR1B1 (0.38) | AKR1B1BACE1CTSDAPPSMN1; SMN2 | |
| SCHEMBL10209437 | 0.88 | AKR1B1 (0.39) | AKR1B1BACE1CTSDAPPANPEP | |
| SCHEMBL892252 | 0.88 | AKR1B1 (0.39) | AKR1B1BACE1CTSDAPPANPEP | |
| SCHEMBL892253 | 0.88 | AKR1B1 (0.39) | AKR1B1BACE1CTSDAPPANPEP | |
| SCHEMBL10265991 | 0.87 | AKR1B1 (0.33) | AKR1B1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | AKR1B1 998/4885BACE1 1/4885CTSD 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.